

## STUDY TEAM ROSTER

### Principal

**Investigator:**        **Lorenzo Berra, M.D.,**

Massachusetts General Hospital

Department of Anesthesia, Critical Care and Pain Medicine

55 Fruit Street

Boston, MA 02114

United States

617-724-2000

lberra@mgh.harvard.edu

**Co-Investigators:**    **Francesco Marrazzo, MD**

Massachusetts General Hospital

Department of Anesthesia, Critical Care and Pain Medicine

55 Fruit Street

Boston, MA 02114

United States

617-724-2000

fmarrazzo@mgh.harvard.edu

**Stefano Spina, MD**

Massachusetts General Hospital

Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
sspina@mgh.harvard.edu

**Francesco Zadek, MD**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
fzadek@mgh.harvard.edu

**Tenzing Sherpa Lama, MD**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
tenzingtsl@gmail.com

**Changhan Xu, MS**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
chxu0618@163.com

**Grant Larson, RA**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
GML35@pitt.edu

**Emanuele Rezoagli, MD**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
emanuele.rezoagli@gmail.com

**Rajeev Malhotra, MD**

Massachusetts General Hospital  
Department of Medicine, Cardiology Division  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
RMALHOTRA@mgh.harvard.edu

**Hui Zheng, MD**

Massachusetts General Hospital  
Department of Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
HZHENG1@mgh.harvard.edu

**Edward A. Bittner, MD**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
ebittner@partners.org

**Kenneth Shelton, MD**

Massachusetts General Hospital  
Department of Anesthesia, Critical Care and Pain Medicine  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
kshelton@mgh.harvard.edu

**Serguei Melnitchouk, MD**

Massachusetts General Hospital  
Department of Cardiac surgery  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
smelnitchouk@mgh.harvard.edu

**Nathalie Roy, MD**

Massachusetts General Hospital  
Department of Cardiac surgery  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
Nathalie.Roy@cardio.chboston.org

**Thoralf M. Sundt, MD**

Massachusetts General Hospital

Department of Cardiac surgery

55 Fruit Street

Boston, MA 02114

United States

617-724-2000

tsundt@mgh.harvard.edu

**William D. Riley, MS, CCP, LP**

Massachusetts General Hospital

Department of Surgery, Cardiac Surgery, Perfusion

Services

55 Fruit Street

Boston, MA 02114

United States

617-724-2000

WRILEY1@PARTNERS.ORG

**Purris Williams, RRT**

Massachusetts General Hospital

Respiratory Care Services

55 Fruit Street

Boston, MA 02114

United States

617-724-2000

PFWILLIAMS@PARTNERS.ORG

**Daniel Fisher, RRT**

Boston Medical Center  
Respiratory Care Services  
One Boston Medical Center Place  
Boston, MA 02118  
United States  
617-638-8000  
daniel.fisher@bmc.org

**Robert Kacmarek, RRT, PhD**

Massachusetts General Hospital  
Respiratory care services  
55 Fruit Street  
Boston, MA 02114  
United States  
617-724-2000  
rkacmarek@partners.org

**Taylor B. Thompson, MD**

Massachusetts General Hospital  
Department of Medicine, Pulmonary & Critical Care Unit  
55 Fruit Street  
Boston, MA 02114  
United States

617-724-2000

TTHOMPSON1@mgh.harvard.edu

**Joseph Bonventre, MD**

Brigham and Women's Hospital

Department of Medicine, Division of Renal Medicine

75 Francis St,

Boston, MA 02115

United States

617-732-5500

JBONVENTRE@BWH.HARVARD.EDU

**Warren Zapol, MD**

Massachusetts General Hospital

Department of Anesthesia, Critical Care and Pain Medicine

55 Fruit Street

Boston, MA 02114

United States

617-724-2000

wzapol@mgh.harvard.edu

**Fumito Ichinose, MD**

Massachusetts General Hospital

Department of Anesthesia, Critical Care and Pain Medicine

55 Fruit Street

Boston, MA 02114



United States

617-724-2000

fichinose@mgh.harvard.edu

**Primary Registry and Trial Identifying  
Number**

**ClinicalTrials:  
NCT02836899**

**Date of Registration**

July 19 2016

**Secondary Identifying Numbers**

IRB ID#: 2016 P001629

**Source(s) of Monetary Support**

National Heart, Lung, and Blood Institute  
(NHLBI) (Award Reference Number K23  
HL128882-01A1)

**Primary Sponsor**

Department of Anesthesiology, Critical care and  
Pain Medicine Massachusetts General Hospital  
Boston, MA 02114

**Contact name**

Lorenzo Berra, MD  
lberra@mgh.harvard.edu

617-724-2000

Department of Anesthesiology, Critical care and  
Pain Medicine Massachusetts General Hospital

55 Fruit Street  
Boston, MA 02114  
United States

**Contact for Scientific Queries**

Lorenzo Berra, MD  
lberra@mgh.harvard.edu  
617-724-2000  
Department of Anesthesiology, Critical care and  
Pain Medicine Massachusetts General Hospital  
55 Fruit Street  
Boston, MA 02114  
United States

**Public Title**

Effect of Nitric Oxide in Cardiac Surgery  
Patients With Endothelial Dysfunction

**Scientific Title**

Prevention of Acute Kidney Injury by Nitric Oxide  
in Prolonged Cardiopulmonary Bypass: A Double-  
Blind Controlled Randomized Trial in Cardiac  
Surgical Subjects with Endothelial Dysfunction

**Countries of Recruitment**

United States

**Health Condition(s) or Problem(s)**

Cardiopulmonary bypass associated-Acute

**Studied**

Kidney Injury

**Intervention(s)** Trial arm 1: Nitric oxide (NO) Group (intervention arm).

NO gas 80 parts-per-million is administered via the oxygenator during CPB, then by inhalation when mechanical ventilation is resumed. Once the subject is extubated, NO gas is delivered by high flow nasal cannula. The treatment begins at the onset of the cardiopulmonary bypass and lasts 24h.

Trial arm 2: Nitrogen (N<sub>2</sub>) Group (Control arm).

N<sub>2</sub> gas is administered via the oxygenator during CPB, then by inhalation when mechanical ventilation is resumed. Once the subject is extubated, N<sub>2</sub> gas is delivered by high flow nasal cannula. The N<sub>2</sub> administration begins at the onset of the cardiopulmonary bypass and lasts 24h.

**Trial Type** Interventional

Allocation: Randomized

Intervention model: Parallel assignment

Blinding: Clinicians blinded to intervention, participants blinded to intervention, study

investigators blinded to intervention, primary outcome assessor blinded to intervention. For safety and gas monitoring, only the clinician administering the test gas remains unblind to the treatment. This clinician is not part of the anesthesia, ICU, or surgical physician team delivering care.

Assignment: Parallel

Primary purpose: Prevention

**Date of First Enrollment** June, 2017

**Target Sample Size** 250 patients

**Recruitment Status** Recruiting

**Key Enrollment Criteria** Inclusion criteria: Age  $\geq$  18 years of age; Elective cardiac or aortic surgery with expected CPB > 90 minutes; Clinical evidence of endothelial dysfunction assessed by a specifically designed questionnaire; Stable preoperative renal function without evidence of a plasma creatinine increase of  $\geq$  0.3 mg/dL within 3 months of study entry and without receiving RRT. Key exclusion criteria:

estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m<sup>2</sup>, mPAP ≥40 mmHg and intravenous (I.V.) contrast infusion within 48 hours before surgery.

**Primary Outcome(s)**

Outcome name: Incidence of Acute Kidney Injury (AKI)

Method of measurement: KDIGO criteria

Time points of interest: 7 days after surgery

**Key Secondary Outcomes**

Outcome name: AKI severity

Method of measurement: KDIGO stages

Time points of interest: 7 days after cardiac surgery

Outcome name: Renal Replacement Therapy

Method of measurement: Medical record review

Time points of interest: Up to 1 year.

Outcome name: Major Adverse Kidney Events (MAKE)

Method of measurement: Medical record

review

Time points of interest: 6 weeks after cardiac surgery.

Outcome name: Organ dysfunction (SOFA score)

Method of measurement: Medical record review

Time points of interest: ICU stay (up to seven days)

Outcome name: Prolonged cardiovascular support

Method of measurement: Medical record review

Time points of interest: 48 hours after cardiac surgery

Outcome name: duration of mechanical ventilation

Method of measurement: Medical record review

Time points of interest: up to 6 weeks

Outcome name: Intensive care unit length of stay (ICU-LOS)

Method of measurement: Medical record review

Time points of interest: up to 6 weeks

Outcome name: Hospital length of stay (LOS)

Method of measurement: Medical record review

Time points of interest: up to 1 year

## **Data and Safety Monitoring Board:**

### **DSMB Chair:**

**John R Prowle, MA MB BChir MSc MD MRCP DICM FFICM**

**Consultant in Intensive Care & Renal Medicine, Barts Health NHS Trust**

**Adult Critical Care Unit, Royal London Hospital, Whitechapel Road, London**

**Phone: +44 20 359 40322 / 40346 (Sec)**

**Email: [john.prowle@bartshealth.nhs.uk](mailto:john.prowle@bartshealth.nhs.uk)**

Michael Fitzsimons, MD

Director Cardiac Anesthesia, Anesthesia Department, Massachusetts General  
Hospital

55 Fruit Street, Boston, MA 02114

Phone: 617-726-3318 Email: [MFITZSIMONS@mgh.harvard.edu](mailto:MFITZSIMONS@mgh.harvard.edu)

Pankaj Arora, MD

Cardiologist and assistant professor at University of Alabama Hospital Division of  
Cardiovascular disease

510 20th St S Fot 705 A, Birmingham, Alabama 35233

Phone: (205) 996-6630 Email: [parora@uabmc.edu](mailto:parora@uabmc.edu)

Responsibilities include: reviewing and evaluating the trial data to ensure participant safety, trial conduct, progress, and efficacy, and making recommendations regarding the continuation, or termination of the trial.